[go: up one dir, main page]

MX2015013590A - Sistemas y metodos para la produccion dirigids de una proteina terapeutica dentro de una celula objetivo. - Google Patents

Sistemas y metodos para la produccion dirigids de una proteina terapeutica dentro de una celula objetivo.

Info

Publication number
MX2015013590A
MX2015013590A MX2015013590A MX2015013590A MX2015013590A MX 2015013590 A MX2015013590 A MX 2015013590A MX 2015013590 A MX2015013590 A MX 2015013590A MX 2015013590 A MX2015013590 A MX 2015013590A MX 2015013590 A MX2015013590 A MX 2015013590A
Authority
MX
Mexico
Prior art keywords
systems
methods
therapeutic protein
production
dirigids
Prior art date
Application number
MX2015013590A
Other languages
English (en)
Other versions
MX387916B (es
Inventor
Matthew R Scholz
Original Assignee
Oisin Biotechnologies
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oisin Biotechnologies filed Critical Oisin Biotechnologies
Publication of MX2015013590A publication Critical patent/MX2015013590A/es
Publication of MX387916B publication Critical patent/MX387916B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/15—Vector systems having a special element relevant for transcription chimeric enhancer/promoter combination
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Se proporcionan constructos de expresión basados en ácido nucleico para la producción dirigida de una proteína terapéutica dentro de una célula que está asociada con envejecimiento, enfermedad, u otra afección. También se proporcionan vectores y sistemas para el suministro de aquellos constructos de expresión basados en ácido nucleico, así como métodos para usar tales constructos de expresión basados en ácido nucleico, vectores, y sistemas para reducir, prevenir, y/o eliminar el crecimiento y/o supervivencia de una célula asociada con edad, enfermedad, o afección y para el tratamiento de una enfermedad o afección que está asociada con una célula asociada con la edad, enfermedad o afección.
MX2015013590A 2013-03-24 2014-03-24 Constructo de expresión para la producción transitoria de una proteína terapéutica casp9 en una célula objetivo senescente humana. MX387916B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361804716P 2013-03-24 2013-03-24
PCT/US2014/031638 WO2014160661A2 (en) 2013-03-24 2014-03-24 Systems and methods for the targeted production of a therapeutic protein within a target cell

Publications (2)

Publication Number Publication Date
MX2015013590A true MX2015013590A (es) 2016-06-06
MX387916B MX387916B (es) 2025-03-19

Family

ID=51625661

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2015013590A MX387916B (es) 2013-03-24 2014-03-24 Constructo de expresión para la producción transitoria de una proteína terapéutica casp9 en una célula objetivo senescente humana.
MX2019010735A MX387280B (es) 2013-03-24 2014-03-24 Sistema para la producción dirigida de una proteína terapéutica dentro de una célula objetivo y uso del sistema.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2019010735A MX387280B (es) 2013-03-24 2014-03-24 Sistema para la producción dirigida de una proteína terapéutica dentro de una célula objetivo y uso del sistema.

Country Status (10)

Country Link
US (4) US20160051700A1 (es)
EP (1) EP2978854A4 (es)
KR (3) KR20160002848A (es)
CN (1) CN105518149A (es)
AU (3) AU2014241622A1 (es)
BR (1) BR112015024605A2 (es)
CA (1) CA2940123C (es)
HK (1) HK1218935A1 (es)
MX (2) MX387916B (es)
WO (1) WO2014160661A2 (es)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11951139B2 (en) 2015-11-30 2024-04-09 Seed Health, Inc. Method and system for reducing the likelihood of osteoporosis
US11998479B2 (en) 2011-02-04 2024-06-04 Seed Health, Inc. Method and system for addressing adverse effects on the oral microbiome and restoring gingival health caused by sodium lauryl sulphate exposure
US12279989B2 (en) 2011-02-04 2025-04-22 Seed Health, Inc. Method and system for increasing beneficial bacteria and decreasing pathogenic bacteria in the oral cavity
US10835560B2 (en) 2013-12-20 2020-11-17 Joseph E. Kovarik Reducing the likelihood of skin cancer in an individual human being
US12533312B2 (en) 2011-02-04 2026-01-27 Seed Health, Inc. Method and system for preventing sore throat in humans
US12257272B2 (en) 2015-12-24 2025-03-25 Seed Health, Inc. Method and system for reducing the likelihood of developing depression in an individual
US11951140B2 (en) 2011-02-04 2024-04-09 Seed Health, Inc. Modulation of an individual's gut microbiome to address osteoporosis and bone disease
US11844720B2 (en) 2011-02-04 2023-12-19 Seed Health, Inc. Method and system to reduce the likelihood of dental caries and halitosis
US10940169B2 (en) 2015-11-30 2021-03-09 Joseph E. Kovarik Method for reducing the likelihood of developing cancer in an individual human being
WO2012177927A1 (en) 2011-06-21 2012-12-27 Mayo Foundation For Medical Education And Research Transgenic animals capable of being induced to delete senescent cells
WO2013158664A2 (en) 2012-04-17 2013-10-24 Kythera Biopharmaceuticals, Inc. Use of engineered viruses to specifically kill senescent cells
US9901080B2 (en) 2012-08-23 2018-02-27 Buck Institute For Research On Aging Transgenic mouse having a transgene that converts a prodrug into a cytotoxic compound in senescent cells
US9901081B2 (en) 2012-08-23 2018-02-27 Buck Institute For Research On Aging Transgenic mouse for determining the role of senescent cells in cancer
US10279018B2 (en) 2012-12-03 2019-05-07 Unity Biotechnology, Inc. Immunogenic compositions for inducing an immune response for elimination of senescent cells
US11998574B2 (en) 2013-12-20 2024-06-04 Seed Health, Inc. Method and system for modulating an individual's skin microbiome
US11026982B2 (en) 2015-11-30 2021-06-08 Joseph E. Kovarik Method for reducing the likelihood of developing bladder or colorectal cancer in an individual human being
US11529379B2 (en) 2013-12-20 2022-12-20 Seed Health, Inc. Method and system for reducing the likelihood of developing colorectal cancer in an individual human being
US11839632B2 (en) 2013-12-20 2023-12-12 Seed Health, Inc. Topical application of CRISPR-modified bacteria to treat acne vulgaris
US11672835B2 (en) 2013-12-20 2023-06-13 Seed Health, Inc. Method for treating individuals having cancer and who are receiving cancer immunotherapy
US11980643B2 (en) 2013-12-20 2024-05-14 Seed Health, Inc. Method and system to modify an individual's gut-brain axis to provide neurocognitive protection
US11826388B2 (en) 2013-12-20 2023-11-28 Seed Health, Inc. Topical application of Lactobacillus crispatus to ameliorate barrier damage and inflammation
US11969445B2 (en) 2013-12-20 2024-04-30 Seed Health, Inc. Probiotic composition and method for controlling excess weight, obesity, NAFLD and NASH
US12005085B2 (en) 2013-12-20 2024-06-11 Seed Health, Inc. Probiotic method and composition for maintaining a healthy vaginal microbiome
US11213552B2 (en) 2015-11-30 2022-01-04 Joseph E. Kovarik Method for treating an individual suffering from a chronic infectious disease and cancer
US11642382B2 (en) 2013-12-20 2023-05-09 Seed Health, Inc. Method for treating an individual suffering from bladder cancer
US11833177B2 (en) 2013-12-20 2023-12-05 Seed Health, Inc. Probiotic to enhance an individual's skin microbiome
US12329783B2 (en) 2013-12-20 2025-06-17 Seed Health, Inc. Method and system to improve the health of a person's skin microbiome
US12246043B2 (en) 2013-12-20 2025-03-11 Seed Health, Inc. Topical application to treat acne vulgaris
WO2017223107A1 (en) * 2016-06-20 2017-12-28 Unity Biotechnology, Inc. Genome modifying enzyme therapy for diseases modulated by senescent cells
CA3047140A1 (en) * 2017-01-09 2018-07-12 Oisin Biotechnologies Constructs for expression of therapeutic proteins in target cells
CN111770763A (zh) * 2018-01-23 2020-10-13 埃森德生物制药有限公司 增强型病毒递送制剂
WO2019204666A1 (en) * 2018-04-18 2019-10-24 Oisin Biotechnologies, Inc. Fusogenic lipid nanoparticles and methods for the manufacture and use thereof for the target cell-specific production of a therapeutic protein and for the treatment of a disease, condition, or disorder associated with a target cell
WO2020023183A1 (en) * 2018-07-24 2020-01-30 So Young Life Sciences Corporation Use of liposomes to deliver a protein and a gene encoding the protein to a live cell
EP3653716A1 (en) * 2018-11-19 2020-05-20 HSF Pharmaceuticals Replication-competent controlled alpha-herpesvirus virus vectors and uses therefore
CN112521511B (zh) * 2020-12-07 2023-03-14 中山大学 一种含EB病毒gB蛋白的自组装纳米颗粒及其制备方法与应用
WO2022245984A1 (en) * 2021-05-19 2022-11-24 Shape Therapeutics Inc. Compositions and methods for modulating payload expression at a transcriptional level
KR102839075B1 (ko) 2022-03-18 2025-07-25 단국대학교 천안캠퍼스 산학협력단 Fast 유전자를 포함하는 레트로바이러스 벡터 및 암 유전자치료제로서의 용도
WO2024073370A2 (en) * 2022-09-27 2024-04-04 The Regents Of The University Of California Methods to rejuvenate human cells through transcriptional reprogramming
CN116240243A (zh) * 2023-03-16 2023-06-09 中国人民解放军军事科学院军事医学研究院 基于dCas9-VP64的转录激活系统构建的A549稳定表达细胞系及其应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992009298A1 (en) 1990-11-23 1992-06-11 Peptide Technology Ltd. The delay, prevention and/or reversal of cell senescence
CA2325088A1 (en) 2000-12-01 2002-06-01 Fusogenix Inc. Novel membrane fusion proteins derived from poikilothermic reovirus
AU2002345658A1 (en) * 2001-06-13 2002-12-23 Eastern Virginia Medical School Methods for targeted expression of therapeutic nucleic acid
CN100361710C (zh) * 2004-06-07 2008-01-16 成都康弘生物科技有限公司 肿瘤细胞专一表达免疫调节因子gm-csf的溶瘤性腺病毒重组体的构建及其应用
AU2008261644B2 (en) 2007-06-12 2014-04-03 Case Western Reserve University Targeted cell death
ES2616728T3 (es) 2008-05-23 2017-06-14 Siwa Corporation Procedimientos y composiciones para facilitar la regeneración
WO2011146862A1 (en) 2010-05-21 2011-11-24 Bellicum Pharmaceuticals, Inc. Methods for inducing selective apoptosis
CA2813300A1 (en) 2010-09-29 2012-04-05 Innovascreen Inc. Recombinant polypeptides for membrane fusion and uses thereof
WO2012177927A1 (en) * 2011-06-21 2012-12-27 Mayo Foundation For Medical Education And Research Transgenic animals capable of being induced to delete senescent cells
CA3047140A1 (en) * 2017-01-09 2018-07-12 Oisin Biotechnologies Constructs for expression of therapeutic proteins in target cells

Also Published As

Publication number Publication date
AU2014241622A1 (en) 2015-11-12
KR20180118259A (ko) 2018-10-30
US20200009268A1 (en) 2020-01-09
AU2021200496A1 (en) 2021-02-25
EP2978854A2 (en) 2016-02-03
US20240382623A1 (en) 2024-11-21
WO2014160661A3 (en) 2014-12-31
CA2940123C (en) 2023-10-10
AU2018220160A1 (en) 2018-09-13
US20160010110A1 (en) 2016-01-14
CN105518149A (zh) 2016-04-20
US20160051700A1 (en) 2016-02-25
CA2940123A1 (en) 2014-10-02
HK1218935A1 (zh) 2017-03-17
KR20200074283A (ko) 2020-06-24
MX387916B (es) 2025-03-19
AU2018220160B2 (en) 2021-05-20
KR20160002848A (ko) 2016-01-08
MX2019010735A (es) 2019-11-05
WO2014160661A2 (en) 2014-10-02
EP2978854A4 (en) 2017-01-11
MX387280B (es) 2025-03-18
BR112015024605A2 (pt) 2017-07-18

Similar Documents

Publication Publication Date Title
MX2015013590A (es) Sistemas y metodos para la produccion dirigids de una proteina terapeutica dentro de una celula objetivo.
MX2024001192A (es) Anticuerpos anti gen 3 de activacion linfocitica (lag-3) y metodos para usarlos.
UY35596A (es) Compuestos para la modulación de quinasas, y sus indicaciones
CU20150119A7 (es) 3-pirimidin-4-il-oxazolidin-2-onas como inhibidores de idh mutante
AR113490A1 (es) CONSTRUCCIONES DE ARNi PARA INHIBIR LA EXPRESIÓN DE PNPLA3 Y MÉTODOS DE USO DE LAS MISMAS
EP3148569A4 (en) Therapeutic tratment of skin disease with recombinant commensal skin microorganisms
CO2017000510A2 (es) Constructos de car
GT201500051A (es) Inhibidores de glucosilceramida sintasa
MX2016015952A (es) Constructos de anticuerpo multiespecifico.
ES2765949T8 (es) Terapia que involucra anticuerpos contra la claudina 18.2 para el tratamiento del cáncer
GT201700033A (es) Anticuerpos anti tigit
BR112017024384A2 (pt) bactérias modificadas para reduzir hiperfenilalaninemia
GT201300215A (es) Inhibidores de glucosilceramida sintasa
NI201300143A (es) Coagonista del receptor de glucagón/glp-1
ECSP13012869A (es) Compuestos y métodos para la modulación de quinasas e indicaciones para los mismos
EA201692425A1 (ru) Модифицированные биополимеры и способы их получения и использования
TR201808169T3 (tr) Rekombinant probiyotik bakteriler .
CR20170197A (es) Proteinas de variantes de secuencias de aminoacidos de cry1da1 activas para lepidópteros
UY35438A (es) Procedimiento para preparar inhibidores de la glucosilceramida sintasa.
MX365403B (es) Peptidos y metodos para usarlos.
EA201691860A1 (ru) Пептидный медикамент в виде сухого порошка
BR112018070139A2 (pt) expressão de proteínas em bactérias gram-negativas em que a razão entre o volume periplasmático e o volume citoplasmático é entre 0,5:1 e 10:1
CL2016002301A1 (es) Cry1d para controlar el gusano de la mazorca del maíz
CR20150640S (es) Aparato para peinar el cabello
MX386144B (es) Inmunopotenciador.